Both the ‘basal-like’ tumours and ‘activated’ stromal subtypes are associated with poorer survival, further supporting the conclusion that high PDCD1LG2 expression is a prognostic marker of poor clinical outcome in patients with PDAC. Here, PDCD1LG2 is linked to neoplasm.